9 results

Certara’s d3 Medicine Partners with the Australian Department of Defence

PRINCETON, NJ – Apr. 5. 2017 – Certara today announced that its d3 Medicine company has been selected to conduct a national audit of Australia’s medical countermeasures (MCM) product research and development (R&D) capabilities and capacity.

https://www.certara.com/pressrelease/certaras-d3-medicine-partners-with-the-australian-department-of-defence/

Certara-Monash University Industry Fellowship Program Receives Funding from MTPConnect

MELBOURNE, AUSTRALIA – October 26, 2017 – MTPConnect today announced it will provide provisional funding to the Certara-Monash University Industry Fellowship Program over two years, with proposed matched funding coming from Certara.

https://www.certara.com/pressrelease/certara-monash-university-industry-fellowship-program-receives-funding-from-mtpconnect/

Using Virtual Twin Technology to Predict Drug Exposure in Individual Patients

In this webinar, Dr. Tom Polasek, a clinical pharmacologist at Certara Strategic Consulting, explained how he used the Simcyp Simulator to predict olanzapine exposure in individual patients. By watching this webinar you will learn how PBPK modeling and simulation technology can be re-purposed to support model-informed precision dosing.

https://www.certara.com/on-demand-webinar/using-virtual-twin-technology-to-predict-drug-exposure-in-individual-patients/

Certara Announces the Formation of a New Practice Area Focused on Global Health

PRINCETON, NJ – July 9, 2019 – Certara has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve equity in health for all people worldwide.

https://www.certara.com/pressrelease/certara-announces-the-formation-of-a-new-practice-area-focused-on-global-health/
1 of 1
Back to top